Regenxbio RGNX
$7.16 −$0.02 (-0.28%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.12 -0.56%
Open$7.00
Prev close$7.18
Day range$6.86 – $7.30
Volume1.06M
Market cap$473.44M
P/E (TTM)–
Dividend yield–
RGNX Stock News
Headlines matching Regenxbio or the RGNX ticker, most recent first.
- H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $21
- Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42
- BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $15
- BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $15 Positive
- A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $45
- Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $18 Positive
- Clear Street Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $45
- H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 Negative
- A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $15 to $32
- Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Sagimet Biosciences, Inc. Class A (SGMT)
- H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 Negative
- H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26
- H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 Negative
- Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $16
- Baird Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $32 Positive
No comments yet — be the first to weigh in on RGNX.
Sign in to join the discussion.